Benitec Biopharma Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2020 (fiscal 2021 first quarter; fiscal year ends June 30). The filing is dated November 13, 2020. Unless noted, financial figures below are in U.S. dollars and thousands.
Business context
Benitec is a development-stage biotechnology company developing genetic medicines using its DNA-directed RNA interference (ddRNAi) platform. Its lead program, BB-301, is an AAV-based “silence and replace” therapy for oculopharyngeal muscular dystrophy (OPMD), and has U.S. and EU orphan drug designations. The company has no approved products and has not generated product-sales revenue. It completed its re-domiciliation from Australia to Delaware in April 2020.
Financial results and liquidity
- Revenue: $55, versus $33 a year earlier, consisting of licensing revenue; no product revenue. The prior-year period included $29 in royalties and $4 in service revenue.
- Operating expenses: $2,745, up from $1,199. Royalties and license fees were $134 (prior year $26); R&D was $774 ($423); and G&A was $1,837 ($750).
- Losses and margins: Operating loss was $2,690 versus $1,166; net loss was $2,718 versus $1,147. Basic and diluted loss per share was $2.45 versus $1.34. Product gross margin is not applicable because the company reports no product sales.
- Cash flow: Operating cash use was $2,360 versus $545; investing cash use was $173 versus $1 provided; financing cash flow was zero versus $1,770 provided. Cash declined by $2,533 before exchange-rate effects.
- Cash and liquidity: Cash and cash equivalents were $7,450 at September 30, down from $9,801 at June 30. Current assets were $8,056 and current liabilities $1,019. Management said cash, including proceeds from the October offering, was expected to fund operations for at least 12 months from the filing date.
- Debt and obligations: The company reported no borrowings and no credit facility. Lease liabilities totaled $359, including $198 current. Total liabilities were $1,180; accumulated deficit was $119,340.
Changes versus the prior-year quarter
Revenue increased modestly, but operating expenses and net loss rose substantially. Management attributed higher R&D expense primarily to a $618 reimbursement from Axovant included in the prior-year comparison, as well as termination of the AMD program. Higher G&A reflected increased corporate and office costs, partly offset by lower employee-related, depreciation, consulting, travel and share-based payment costs. Other income moved to a $28 net loss from $19 of income, including a $54 foreign-currency transaction loss.
Outlook, risks and unusual items
- On October 6, 2020, Benitec closed an underwritten offering of shares and pre-funded warrants, raising approximately $11.5 million gross and $9.9 million net. These proceeds were not included in September 30 cash.
- COVID-19 delayed BB-301 IND-enabling work, including a tissue-transduction study, by several months. The study had recently begun and initial preclinical cohort dosing had proceeded without incident. The company said further effects on timelines and costs remained uncertain.
- Management expects R&D and public-company G&A costs may increase and anticipates continued losses. Future funding needs depend on development costs, regulatory progress, collaborations, licensing and other factors; additional financing may be needed.
- The company said it would not claim Australian government R&D grants going forward. It also reported no material legal proceedings, no material off-balance-sheet arrangements, and no material changes to the risk factors in its prior Form 10-K.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the timing and remaining scope of BB-301 preclinical and IND-enabling milestones, including any continuing COVID-19-related delays.
- Assess cash runway using the October offering’s net proceeds alongside the reported quarterly operating cash use and expected cost increases.
- Review whether licensing, collaboration or other revenue can grow, given the small revenue base and lack of product sales.
- Track share count and dilution: 1,108,374 shares were reported outstanding at September 30; the filing reports 4,405,469 shares outstanding at November 9, after the offering and related securities.
- Check the original filing for the precise composition and terms of the October offering and any subsequent financing or program updates.